Vikas Dandekar (@vikasreports) 's Twitter Profile
Vikas Dandekar

@vikasreports

Journalist - Indian pharma & healthcare. Views own

[email protected]

ID: 29193745

linkhttp://www.etprime.com calendar_today06-04-2009 12:53:34

30,30K Tweet

13,13K Followers

466 Following

Teena Thacker (@teensthack) 's Twitter Profile Photo

The All India Institute of Medical Sciences (@AIIMS) is reeling under an acute shortage of staff, with 430 posts of doctors and 2,109 posts of faculty members lying vacant at the country’s premier medical institute.  Ministry of Health

The All India Institute of Medical Sciences (@AIIMS) is reeling under an acute shortage of staff, with 430 posts of doctors and 2,109 posts of faculty members lying vacant at the country’s premier medical institute. 
<a href="/MoHFW_INDIA/">Ministry of Health</a>
Teena Thacker (@teensthack) 's Twitter Profile Photo

The government may offer easier market access for US medical device firms as part of its efforts to mitigate the potential impact of the US #tariff threat on Indian exports and create leverage in trade negotiations, multiple people aware of the matter told ET. #medical #devices

The government may offer easier market access for US medical device firms as part of its efforts to mitigate the potential impact of the US #tariff threat on Indian exports and create leverage in trade negotiations, multiple people aware of the matter told ET.
#medical #devices
Vikas Dandekar (@vikasreports) 's Twitter Profile Photo

It starts: Eli Lilly launches #Mounjaro in India for obesity and type 2 diabetes treatment. Big market to tap. 100 million diabetes patients and an equal set of population with obesity. #weightloss #obesity Teena Thacker

Teena Thacker (@teensthack) 's Twitter Profile Photo

.Eli Lilly and Co.’s global CEO David Ricks is spearheading the worldwide launch of popular diabetes & anti-obesity drugs #Mounjaro #Zepbound.The chief of $45-billion US-pharma giant spoke on a range of topics, from the next generation of weight loss drugs to trade barriers Vikas Dandekar

.<a href="/EliLilly/">Eli Lilly and Co.</a>’s global CEO David Ricks is spearheading the worldwide launch of popular diabetes &amp; anti-obesity drugs #Mounjaro #Zepbound.The chief of $45-billion US-pharma giant spoke on a range of topics, from the next generation of weight loss drugs to trade barriers
<a href="/VikasReports/">Vikas Dandekar</a>
Vikas Dandekar (@vikasreports) 's Twitter Profile Photo

On his recent visit to India, Eli Lilly's Global CEO David Ricks spoke on a wide band of issues on our Economic Times The Morning Brief #podcast Teena Thacker ... thanks Anirban Chowdhury and his cracker team for this very important episode. open.spotify.com/episode/0u7OP4…

Economic Times (@economictimes) 's Twitter Profile Photo

#ETMorningBriefPodcast: Corner Office Conversation with #EliLilly's Global CEO David Ricks | Listen in with Vikas Dandekar & Teena Thacker🎧 🎙️ economictimes.indiatimes.com/news/morning-b…

Teena Thacker (@teensthack) 's Twitter Profile Photo

Indian drug makers like @DrReddy’s Labs, Zydus Lifesciences Ltd. and MSN Labs are setting up new manufacturing capacities as they race to launch copies of blockbuster anti-diabetes and weight-loss drugs #Wegovy & #Ozempic. Reporting with Vikas Dandekar

Indian drug makers like @DrReddy’s Labs, <a href="/ZydusUniverse/">Zydus Lifesciences Ltd.</a> and MSN Labs are setting up new manufacturing capacities as they race to launch copies of blockbuster anti-diabetes and weight-loss drugs #Wegovy &amp; #Ozempic.

Reporting with <a href="/VikasReports/">Vikas Dandekar</a>
Teena Thacker (@teensthack) 's Twitter Profile Photo

A new oral pill for weight loss has moved a step closer to commercial launch, raising hopes for those who suffer from “needle phobia” & have avoided taking Mounjaro/Wegovy, the two blockbusters. Oral drug-orforglipron, showed encouraging results in phase-III trials Vikas Dandekar

A new oral pill for weight loss has moved a step closer to commercial launch, raising hopes for those who suffer from “needle phobia” &amp; have avoided taking Mounjaro/Wegovy, the two blockbusters. Oral drug-orforglipron, showed encouraging results in phase-III trials
<a href="/VikasReports/">Vikas Dandekar</a>
ETPharma (@etpharma) 's Twitter Profile Photo

Data Fudging and the US FDA’s Rap on Raptim: Lessons Not Learnt #Pharma I #Drugs I #CRO I #Data I #Trials I #Data_integrity I #Violations I #Health I FDA I #NDA I #ANDAs I #IVPT_Study I Vikas Dandekar I #Ranbaxy Read more: pharma.economictimes.indiatimes.com/news/pharma-in…

Rica BhattacharyyaET (@ricab_et) 's Twitter Profile Photo

Weight-loss medications like Mounjaro and Wegovy in India may lead to a decline in bariatric surgeries, say top doctors from reputed hospitals. But those who are morbidly obese may still need surgery. A well-balanced view from ⁦Economic Times⁩ search.app/fPj9QxQnmwjs4x…

Vikas Dandekar (@vikasreports) 's Twitter Profile Photo

Here Rica BhattacharyyaET covers an important angle that went largely untapped in India as fat busters are launched. Bariatric surgeries will be affected, experts say, but it is not the end of the road...Good read !!

Kiran Mazumdar-Shaw (@kiranshaw) 's Twitter Profile Photo

India must consider adopting innovative methods such as organoids, in vitro, and in-silico methods as part of regulatory reforms for biosimilars drug approvals.

India must consider adopting innovative methods such as organoids, in vitro, and in-silico methods as part of regulatory reforms for biosimilars drug approvals.
Economic Times (@economictimes) 's Twitter Profile Photo

If your journey reflects #leadership, #resilience, and results, nominate yourself to be part of the #ET40UnderForty list. Apply now: et40under40.in Last date: to apply: May 21, 2025 (Wed)

If your journey reflects #leadership, #resilience, and results, nominate yourself to be part of the #ET40UnderForty list.
Apply now: et40under40.in
Last date: to apply: May 21, 2025 (Wed)
Teena Thacker (@teensthack) 's Twitter Profile Photo

A huge number of MSME pharma companies are manufacturing substandard drugs. According to the data by India’s drug regulatory authority for the month of April, majority of these companies are making drugs that failed safety standards & have been found to be not of standard quality

A huge number of MSME pharma companies are manufacturing substandard drugs. According to the data by India’s drug regulatory authority for the month of April, majority of these companies are making drugs that failed safety standards &amp; have been found to be not of standard quality